TY  - JOUR
AU  - Mai, Elias K
AU  - Miah, Kaya
AU  - Bertsch, Uta
AU  - Dürig, Jan
AU  - Scheid, Christof
AU  - Weisel, Katja C
AU  - Kunz, Christina
AU  - Munder, Markus
AU  - Lindemann, Hans-Walter
AU  - Merz, Maximilian
AU  - Hose, Dirk
AU  - Jauch, Anna
AU  - Seckinger, Anja
AU  - Luntz, Steffen
AU  - Sauer, Sandra
AU  - Fuhrmann, Stephan
AU  - Brossart, Peter
AU  - Elmaagacli, Ahmet
AU  - Goerner, Martin
AU  - Bernhard, Helga
AU  - Hoffmann, Martin
AU  - Raab, Marc S
AU  - Blau, Igor W
AU  - Hänel, Mathias
AU  - Benner, Axel
AU  - Salwender, Hans J
AU  - Goldschmidt, Hartmut
TI  - Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
JO  - Leukemia
VL  - 35
IS  - 3
SN  - 1476-5551
CY  - London
PB  - Springer Nature
M1  - DKFZ-2020-01574
SP  - 809-822
PY  - 2021
N1  - 2021 Mar;35(3):809-822
AB  - Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8
LB  - PUB:(DE-HGF)16
C6  - pmid:32684633
DO  - DOI:10.1038/s41375-020-0976-9
UR  - https://inrepo02.dkfz.de/record/157345
ER  -